| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
SB297006 (SB-297006) is an antagonist of CCR3 (Chemokine receptor, IC50 = 39 nM) with anticancer activity. It dramatically suppresses neurosphere formation and proliferation in neural progenitor cells treated with CCL11. Leukocytes have CCR3, which is the main receptor for CCL11. Neural progenitor cells (NPCs) exhibited the functional chemokine receptor CCR3, and when CCL11 was applied to NPCs, the CCR3 receptor antagonist SB297006 dramatically reduced NPC proliferation and neurosphere formation.
| Targets |
CCR3
CCR3 (C-C chemokine receptor type 3) antagonist, blocks CCL11 binding to CCR3 on neural progenitor cells[1] |
|---|---|
| ln Vitro |
SB297006 is a CCR3 antagonist dramatically reduces neurosphere formation and proliferation in CCL11-treated neural progenitor cells (NPCs) at 100 μM[1].
Inhibited CCL11-induced neural progenitor cell migration: Mouse neural progenitor cells (NPCs) were pre-incubated with SB297006 (100 μM) for 30 minutes, then stimulated with CCL11 (2 μg/ml). Migration was measured using a μ-slide Chemotaxis 3D system. SB297006 significantly reduced CCL11-induced migration compared to CCL11 alone (P<0.05) [1] - Inhibited CCL11-induced neural progenitor cell proliferation: Mouse embryonic and infant NPCs were treated with CCL11 (2 μg/ml) alone or combined with SB297006 (100 μM). CCK-8 assays at 3 days showed that SB297006 significantly blocked CCL11-induced proliferation (P<0.05) [1] - Inhibited CCL11-induced neurosphere formation: Mouse embryonic NPCs treated with CCL11 (2 μg/ml) formed neurospheres at 3 days post-treatment. Co-treatment with SB297006 (100 μM) prevented neurosphere formation, confirming inhibition of CCL11-induced proliferation and aggregation [1] - Had no significant effect on NPC viability when used alone: NPCs treated with SB297006 (100 μM) without CCL11 showed no significant difference in viability compared to vehicle control [1] |
| Cell Assay |
Neural progenitor cells (NPCs) are stimulated with CCL11 (2 μg/mL) after 30 minutes of incubation with the CCR3 antagonist SB297006 (100 μM) to assess CCR3 blocking. NPCs are subjected to CCK-8 assays following a 3-day culture period.
CCR3 antagonist functional assay: Mouse neural progenitor cells were pre-incubated with SB297006 (100 μM) for 30 minutes, then stimulated with CCL11 (2 μg/ml). After 3 days, CCK-8 assay measured proliferation inhibition. The experiment confirmed that SB297006 specifically blocked CCL11-CCR3 signaling in NPCs [1] |
| References | |
| Additional Infomation |
SB297006 is a selective CCR3 antagonist that blocks the binding of CCL11 (eosinophil chemokine) to its receptor CCR3 expressed on neural progenitor cells [1]. SB297006 specifically inhibits CCL11-induced neural progenitor cell migration and proliferation, suggesting that the CCL11-CCR3 signaling pathway plays an important role in neurogenesis and neural progenitor cell mobilization after brain injury [1]. The inhibition of CCL11-induced effects by SB297006 is specific because it does not affect other CC chemokines (CCL2, CCL3, CCL4, CCL5, CCL9, CCL12, CCL20, CCL22), which are also upregulated in damaged brain tissue [1]. SB297006 may have the potential to treat neonatal hypoxic-ischemic brain injury and other neurological disorders by regulating neural progenitor cell migration and proliferation [1].
|
| Molecular Formula |
C₁₈H₁₈N₂O₅
|
|
|---|---|---|
| Molecular Weight |
342.35
|
|
| Exact Mass |
342.122
|
|
| Elemental Analysis |
C, 63.15; H, 5.30; N, 8.18; O, 23.37
|
|
| CAS # |
58816-69-6
|
|
| Related CAS # |
|
|
| PubChem CID |
9840971
|
|
| Appearance |
White to off-white solid powder
|
|
| Melting Point |
121 °C
|
|
| LogP |
3.413
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
7
|
|
| Heavy Atom Count |
25
|
|
| Complexity |
463
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
O(C([H])([H])C([H])([H])[H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])[N+](=O)[O-])N([H])C(C1C([H])=C([H])C([H])=C([H])C=1[H])=O)=O
|
|
| InChi Key |
BEZXGSZPWXRHIN-INIZCTEOSA-N
|
|
| InChi Code |
InChI=1S/C18H18N2O5/c1-2-25-18(22)16(19-17(21)14-6-4-3-5-7-14)12-13-8-10-15(11-9-13)20(23)24/h3-11,16H,2,12H2,1H3,(H,19,21)/t16-/m0/s1
|
|
| Chemical Name |
ethyl (2S)-2-benzamido-3-(4-nitrophenyl)propanoate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9210 mL | 14.6049 mL | 29.2099 mL | |
| 5 mM | 0.5842 mL | 2.9210 mL | 5.8420 mL | |
| 10 mM | 0.2921 mL | 1.4605 mL | 2.9210 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
 The cell culture assay for NPCs.Stem Cell Res Ther.2017 Feb 7;8(1):26. |
|---|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA